OncoMatch/Clinical Trials/NCT05844046
Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients
Is NCT05844046 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies durvalumab, tremelimumab, bevacizumab for hepatocellular carcinoma.
Treatment: durvalumab, tremelimumab, bevacizumab — This is a randomized, open-label, multi-center, international, Phase II study to assess the efficacy and safety of sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma. Patients will be randomized in a 1:1 ratio to one of the following arms: Arm A: initial treatment with durvalumab plus tremelimumab followed by treatment escalation with the addition of bevacizumab upon radiological progression or in the absence of objective response Arm B: up-front treatment with durvalumab, tremelimumab and bevacizumab Patients will be stratified according to macrovascular invasion and etiology of liver disease (viral etiologies versus others).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Must not have received prior systemic therapy for HCC.
Cannot have received: durvalumab and/or tremelimumab (durvalumab, tremelimumab)
Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
Lab requirements
Blood counts
Adequate organ and marrow function
Kidney function
Adequate organ and marrow function
Liver function
Child-Pugh Score class A
Child-Pugh Score class A; Adequate organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify